ABSTRACT-The effect of lactation on the pharmacokinetics of phenobarbital (PB) after delivery was studied in female rats. Non-pregnant animals received PB 20 mg/kg/day twice for 6-7 days before mating, during pregnancy and after delivery. Chronic PB did not significantly influence changes in the body weight of rats after delivery. On the first post-delivery day, the plasma PB concentration in the PB-treated rats was significantly higher than that in PB-treated, non-pregnant rats (non-pregnant rats); and thereafter, it grad ually decreased until ablactation on the 20th day. After ablactation, plasma PB concentrations gradually returned to the level before delivery. In PB-treated rats, pharmacokinetic parameters (Cmax, AUC0-12) of PB between 0 and 12 hr after a single oral administration were significantly decreased during lactation. These results suggest that PB administered during lactation is transferred in part to offspring through maternal milk.
The number of epileptic women undergoing treatment and who desire children are increasing. These patients should continue to take antiepileptic drugs during preg nancy, delivery and lactation for seizure control.
After delivery, mothers have been encouraged to nourish their children by breast feeding because of the immunological (1), nutritional (2) and psychological (3) advantages of maternal milk. In addition, breast feeding prevents withdrawal symptoms such as vomiting, restless ness, hyperactivity and tremor, which appear in babies delivered from women taking antiepileptic or sedative drugs (4) .
Many investigators have reported the influences of anti epileptic drugs on the offspring of epileptic mother (5 8) . The frequency of maternal psychomotor seizures increases during early puerperium (9) . However, there are few reports describing the pharmacokinetics of anti epileptic drugs in the mother during lactation (10) .
We developed a means of measuring plasma phenobar bital (PB) concentrations in small amounts (60 p1) of rat blood, which allows repeated evaluations (11) . Using this method, we found that pregnancy itself does not affect the plasma level and pharmacokinetic parameters of PB during chronic treatment when a fixed dosage is given according to maternal body weight (12) . In the present study, we examined the pharmacokinetics of PB during lactation in rats.
MATERIALS AND METHODS

Chemicals
PB was purchased from Sigma Chemical Co. (St. Louis, MO, USA). For oral administration, PB was sus pended in 0.5% sodium carboxymethylcellulose (CMC). Acetanilide (Wako Pure Chemical Industries, Osaka) was used as an internal standard (IS) and dissolved at a con centration of 2 pg/ml in 50% methanol. All other re agents were of guaranteed grade.
Animals
Female Wistar rats weighing 195 to 210 g at the begin ning of the study were obtained from Charles River Japan, Inc. (Atsugi). They were housed in the ex perimental animal center of Okayama University Medical School at a controlled ambient temperature of 221C with 60% relative humidity and under a 12-hr light/dark cycle (light on from 7:00).
Experimental procedure
Female rats were divided into 3 groups: a) PB-treated and undelivered, b) PB-treated and lactating and c) PB untreated and lactating group. The effect of lactation on the plasma PB level (trough level) before daily adminis tration was compared between groups a and b. In addi tion, the effect of lactation on the pharmacokinetic parameters following PB administration was studied in groups b and c. Each animal was measured and PB (20 mg/kg) was weighed by gavage to groups a and b twice (at 07:00 and 19:00) every day throughout the experiment. In group c, 0.5% CMC (vehicle) was orally administered ac cording to the same schedule. Before the administration of PB or vehicle at 07:00, blood was collected from the tail vein into 60-tit capillaries, and plasma PB concentra tions were measured. When the plasma concentrations of PB reached the steady state (7 to 10 days after starting administration), female and male rats were mated for 5 days.
Each pregnant rat in groups a and b was delivered of 6 to 16 pups. To standardize the amount of lactation, we selected 3 rats, which had given birth to 13 to 16 off spring, for the study of the lactating group. Twenty days after delivery, the pups were weaned.
During early lactation (2 4 days after delivery) and mid lactation (10-11 days after delivery) and after dis continuing of breast feeding (2 3 days after weaning), we examined time-course changes in the plasma PB concen trations from 0 to 12 hr after a single oral administration of PB in both lactating groups b and c. Food was withheld for 12 hr before and throughout this experi ment.
Determination of plasma PB level
After centrifugation at 12,000 rpm for 3 min in a hematocrit centrifuge (Compur M 1100; Compur Elec tronic GmbH, Munich, Germany), 20 ,al of plasma with 0.1 pg of IS was passed through a Bond Elut cartridge C-18 solid-phase extraction column (1-ml volume, No. 1210-2001; Varian SPP, Harbour City, CA, USA), which was washed twice with 1 ml of methanol and 1 ml of 0.01 M KH2PO4. The samples were eluted with 250 pl of methanol. The eluate (20 i1) was applied to a high per formance liquid chromatograph (HPLC) system, com posed of a pump (type 510; Waters-Millipore, Milford, MA, USA), an automatic sample processor (Type 710B), an ultraviolet monitor (Type 481), and a data module (Type 730). The analytical column was a LiChroCART RP-18e (4 ,um particle size, 4 x 125 mm; Cica-Merck Co., Tokyo). The mobile phase was a mixture of acetoni trile/0.01 M KH2PO4 (25/75, v/v), the flow rate was 0.8 ml/min, and PB was detected at 210 nm. The retention times of IS and PB were 4.6 and 7.8 min, respectively.
Pharmacokinetic analysis Pharmacokinetic parameters were obtained from the PB plasma concentration-time data from each animal, using a personal computer program for nonlinear least squares regression analysis (MULTI) (13) . Time at maxi mal concentration (Tmax), maximal plasma concentration (Cmax), area under the plasma concentration-time curve from 0 to 12 hr (AUC0_ 12) and mean residence time (MRT) were calculated by standard linear trapezoidal integration.
Statistical analyses
Results are expressed as means±S.E.M. Data were statistically evaluated by the unpaired Student's t-test followed by repeated-measurement analysis of variance (ANOVA) between chronically PB treated, lactating and non-lactating groups. The pharmacokinetic parameters were evaluated by the paired Student's t-test between the control (no lactation) and three lactation stages (early, mid and after weaning). A value of P<0.05 was consi dered statistically significant.
RESULTS
Changes in plasma PB concentrations during chronic ad ministration in lactating and non-lactating rats Daily PB administration did not affect the body weight of lactating and undelivered rats compared with the un treated control (data not shown). Figure 1 shows changes in plasma PB concentrations (before daily administra tion) in rats with or without lactation that were chroni cally treated with PB. As evaluated by repeated ANOVA, the difference between chronically PB-treated, lactating and non-lactating groups was significant (F=9.351, P<0.05).
On the first day after delivery, the plasma PB concentration in lactating rats was significantly higher than that in undelivered rats. The elevated plasma PB concentration in the delivered group rapidly decreased on the second day after delivery and thereafter, PB concen trations gradually decreased until ablactation. PB con centrations of the group from 8 to 22 days after delivery were significantly lower than those of the undelivered groups. After weaning on the 20th day after delivery, maternal plasma PB concentrations gradually returned to levels on the 2nd day after delivery.
Effect of lactation on pharmacokinetics of PB Figure 2 shows the time-course changes in plasma PB concentrations after a single oral (20 mg/kg, p.o.) ad ministration of PB during early (2-4 days after delivery) lactation. Plasma PB concentrations in both chronically PB-treated and untreated rats rapidly increased to a maxi mum of 31.2 and 16.2 pg/ml at 1 and 2 hr, respectively, and then gradually decreased. During mid (10-11 days after delivery) lactation in chronically PB-treated and untreated rats, the plasma PB concentrations rapidly increased to a maximum of 32.8 and 23.3 pg/ml at 2 and 1 hr, respectively, and then decreased faster than in the early stage of lactation (Fig.  3) . Figure 4 shows changes in the plasma PB concentra tions following the oral administration of PB (20 mg/kg, p.o.) after ablactation (2-3 days after weaning from the mother). Plasma PB concentrations in chronically PB treated and -untreated rats rapidly increased to a maxi mum of 46.2 and 23.9 pg/ml at 2 hr, respectively, and then gradually decreased in a manner similar to the time course changes during early lactation. Pharmacokinetic parameters of PB in delivered and lactating rats are shown in Table 1 . In mid lactation, Cm, AUCo_12 and MRT decreased, when compared with the control rats (pre-delivery and non-lactating rats). Both Cm and AUC0_ 12 in lactating rats were significantly lower than those in control rats. In the post-lactation rat, the pharmacokinetic parameters (Cmax, AUCo_12) were almost at control levels. 
DISCUSSION
The present study showed that a) chronic PB adminis tration did not affect the body weight of lactating and undelivered rats; b) the plasma concentration of PB decreased gradually during lactation until weaning on the 20th day; c) after ablactation, plasma PB concentrations returned to pre-lactation levels and d) the Cmax and AUCO_12 values significantly decreased during lactation. These results suggest that lactation causes a decrease in the plasma PB concentration in rats. Table 1 .
Effect of lactation on pharmacokinetic parameters PB at a single dose of 20 mg/kg was administered orally by gavage to the chronically P13-treated groups. Data indicate means±S.E.M. calcu lated by the personal computer program MULTI. AUC and MRT values were calculated from 0 to 12 hr after oral administration. Each asterisk indicates a significant difference from the control in each experimental group (paired t-test).
Plasma PB concentrations of rats on the first day after the delivery were markedly higher than those of undeli vered rats (Fig. 1) . Because the PB dose was adjusted in proportion to the increasing body weight during preg nancy, to a fixed ratio throughout the experiment, and because body weight increased during late part of preg nancy, the increased plasma PB concentrations on the first day after delivery seemed to be due mainly to the acute loss of distribution volume, which had been sup plied to the fetus.
Long-term PB administration induces the enzyme that metabolizes it (14) . In fact, Tmax and MRT was decreased by long-term PB administration (Table 1) . Davis et al. (15) reported that hepatic enzyme levels alter during pregnancy. Therefore, long-term PB administration should affect pharmacokinetic parameters during lacta tion. The present findings that both Tmax and MRT significantly decreased (Table 1) during long-term PB administration suggest enzyme induction. However, the pharmacokinetic parameters in PB-treated and -untreated groups were similar during lactation (Table 1) . Thus, long-term PB administration does not affect pharmaco kinetic parameters during lactation.
As shown in Table 1 , during early and mid lactation in both chronically PB-untreated and PB-treated groups, Cmax and AUCO_ 12 values were significantly lower than those in the control rats. After ablactation, these phar macokinetic parameters returned to control values. It is likely that the decreases in Tmax, Cmax, AUCO_12 and MRT mainly reflect PB transfer to the increased lactation due to growing demands of the pups, and the increased values may be due to stopping lactation. Many investigators have reported that antiepileptic drug concentrations alter during pregnancy because of physiological changes in hormonal factors (16) , renal function (16, 17) and protein binding (16) . The decrease in Tm, Cmax, AUCO_ 12 and MRT during lactation and changes in MRT after weaning may be affected by physiological changes caused by preg nancy or by hormonal changes during lactation.
Recently, we reported that pregnancy itself does not affect plasma levels and pharmacokinetic parameters of PB when chronically administered if the dosage is fixed according to maternal body weight, which includes that of the fetus (12) . In the present study, plasma PB con centrations in chronic PB-treated rats after delivery grad ually decreased when the dosage was fixed according to maternal weight excluding that of the pups. Thus, we calculated the plasma PB concentrations when the dosage was determined according to the weight of the mother plus that of the pups. This calculation showed that plas ma PB concentrations gradually elevated due to the in creased weight of the offspring during late lactation (data not shown). Therefore, we corrected the plasma PB con centration using the human milk/plasma ratio of 0.35 reported by Kaneko et al. (18, 19) , although we have no data on the milk/plasma ratio of PB concentrations in rats because measuring PB concentrations in rat milk is difficult. From this calculation, the corrected plasma PB concentrations were relatively constant during lactation. Thus, we suggest that plasma PB can be maintained at a constant concentration by adjusting the dose to fit the corrected body weight that includes a 35% increase to ac count for the weight of the pups.
In conclusion, the present study suggests that decreased plasma PB concentrations after delivery and changes in the pharmacokinetics of PB during the lactation in rats result from the transfer of PB to the offspring through maternal milk. The present results also suggest that the loss of PB during lactation reflects a constant PB concen tration in the plasma of the lactating patient.
